Durvalumab and tremelimumab in patients with advanced rare cancer: a multi-centre, non-blinded, open-label phase II basket trial
Janet Dancey, Rahma Jamal, Diane Provencher, Hal Hirte et al.
Citations
3 citations
Journal
EClinicalMedicine
Topics
Cancer Immunotherapy and Biomarkers
Field-Weighted Citation Impact (FWCI)
0.85
article
Durvalumab and tremelimumab in patients with advanced rare cancer: a multi-centre, non-blinded, open-label phase II basket trial
Janet Dancey, Rahma Jamal, Diane Provencher, Hal Hirte, Abha A. Gupta, Eric Winquist, Christine Elser, Sébastien J. Hotte, Thierry Alcindor, Torsten O. Nielsen, D. Jonker, Tricia R. Cottrell, Ming‐Sound Tsao, Anna V. Tinker, Quincy S. Chu, Christian Kollmannsberger, Monika K. Krzyzanowska, John Hilton, Wei Tu, Siwei Zhang, Joana Sederias, Ralph Wong
article en
3 citations
Abstract
No abstract available for this paper.
Publication Tag
EClinicalMedicineVol. 79
Institutions
BC Cancer Agency (CA), University Health Network (CA), Queen's University (CA), Cancer Care Ontario (CA), Juravinski Cancer Centre (CA), Ottawa Hospital (CA), McGill University Health Centre (CA), Princess Margaret Cancer Centre (CA), CancerCare Manitoba (CA), BC Studies (CA), Centre Hospitalier de l’Université de Montréal (CA), Ottawa Hospital Research Institute (CA), McGill University (CA), Hamilton Health Sciences (CA)
Funders
AstraZeneca, Canadian Cancer Society, Canadian Cancer Society Research Institute